CBC News – Jun 25, 201
Ministry of Health launching consultations on a health sector payment transparency program.
[Excerpt] B.C. could soon require drug companies to reveal any payments they make to doctors and other health professionals in an attempt to be transparent about any potential conflicts of interest.
If it goes ahead, the province’s proposed health sector payment transparency program would cover payments and services handed out by pharmaceutical companies and equipment manufacturers.
“I think what it does is it puts the patient more at the centre of health care, so the patient has knowledge and responsibility,” Health Minister Adrian Dix told CBC.
“I think it also helps doctors as well, who are sometimes questioned on these matters and who I think in general would greatly prefer a transparent system.”
Payments and transactions with health authorities and other publicly funded health organizations would also need to be disclosed through the proposed program.
The ministry has asked 50 groups and individuals to consult on the idea over the summer, including health professional colleges, patient advocacy organizations and pharmaceutical companies.
Dix wasn’t able to give an estimate for when such a program might become a reality, explaining that it depends on what comes out of the consultations this summer.
But he said the issue of undue influence from pharmaceutical companies has been on his radar for years.
“There are hundreds and hundreds of what are known as drug detailers in B.C., whose job essentially is to sell … prescription drugs, mainly to a relatively small number of doctors,” he said.
“Those relationships sometimes have been problematic.”
Calls for Canada-wide disclosure
The Ontario government recently drafted new regulations requiring disclosure of payments by drug companies, and a group of health researchers and doctors called Open Pharma is lobbying the federal government to make disclosure mandatory across the country.
“Such reporting is not intended to shame prescribers or impede partnerships between industry and professionals,” Open Pharma members wrote in a 2017 letter to the federal Health Ministry.